唑来膦酸和伊班膦酸钠治疗恶性肿瘤骨转移的成本- 效用分析.

Objective: To evaluate the economical effect of zoledronic acid and ibandronate sodium in the treatment of patients with bone metastases of malignant tumors. Methods: A retrospective analysis of 86 cases of bone metastases of malignant tumors in × Hospital from January 2020 to January 2022, of which 46 cases were treated with zoledronic acid (group A) and 40 cases were treated with ibandronate sodium (Group B), compare the pain control effect, adverse reactions and the SF-36 score between the two groups, and summarize the cost of the two treatment options, and use the principles of pharmaco economics to conduct a cost-utility analysis. Results: The pain control rate in group A was 82.61%, which was not statistically different from 85.00% in group B (P>0.05); after treatment, the physiological function (PF) and physiological function (RP) in the SF-36 score of the two groups, body pain (BP), general health (GH), social function (SF), mental health (MH), emotional function (RE), and vitality (VT) were significantly higher than those before treatment (P<0.05), but the group There was no statistically significant difference between groups (P>0.05); the incidence of adverse reactions in group A and group B was similar, and the difference was not statistically significant (P>0.05); the drug cost (C1) and total cost (C) of group A were respectively (4052.50±80.50) yuan and (4453.87±123.56) yuan, which were higher than (2025.50±70.15) yuan and (2395.44±109.17) yuan in group B, and the differences were statistically significant (P<0.05); group A cost- The utility ratio (CUR) was judged by the SF-36 scale to be 4189.94, and that of group B was 2829.17. Conclusion: Considering the effectiveness and economy of the drug, the use of ibandronate sodium in the treatment of bone metastases of malignant tumors. [ABSTRACT FROM AUTHOR]